83% pCR in ER-negative patients. Anthracycline-free. A striking new benchmark for HER2+ disease.
This clip explores why DESTINY-Breast11 is generating so much excitement — and why clinicians are already debating how fast to bring this strategy into practice.
Neoadjuvant T-DXd: Why DESTINY-Breast11 Data Turned Heads
You may also like
Recommended Videos
